

asx announcement

MESOBLAST FEATURED AT INTERNATIONAL SCIENTIFIC CONFERENCES

Clinical programs for congestive heart failure, degenerative spinal diseases, and bone marrow transplantation highlighted

Melbourne, Australia, 20 September 2010: Clinical advances by regenerative medicine company Mesoblast Limited (ASX:MSB; ADR:MBLTY) were featured prominently at the 39th annual meeting of the International Society for Experimental Hematology (ISEH) and the Tissue Engineering and Regenerative Medicine International Society (TERMIS) Asia Pacific meeting, both held over the past several days.

More than 500 international participants attended the ISEH and TERMIS conferences which promoted scientific knowledge and clinical application of stem cell research, basic haematology, immunology, cell and gene therapy, tissue engineering and regenerative medicine.

Mesoblast's scientists and clinicians were highlighted at plenary sessions and special symposia, which featured the Company's clinical programs, including those for congestive heart failure, degenerative spinal disease, and bone marrow transplantation. International delegates were told that the clinical results indicate that Mesoblast's technology has the potential to improve both quality of life and survival outcomes in life-threatening diseases.

Mesoblast will continue to ensure that its clinical achievements and cutting edge research are highlighted and recognised at respected and prestigious conferences, meetings attended by key opinion leaders, and peer-reviewed publications.

About Mesoblast Limited

Mesoblast Limited (ASX: MSB; ADR: MBLTY) is a world leader in commercialising biologic products for the broad field of regenerative medicine. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction, culture and uses of adult Mesenchymal Precursor Cells (MPCs). www.mesoblast.com

For further information, please contact:

Julie Meldrum
Corporate Communications Director
Mesoblast Limited
T: + 61 (03) 9639 6036
E: julie.meldrum@mesoblast.com
W: www.mesoblast.com